Iontera
Providence
About Iontera
Iontera is pioneering in the design and development of intelligent transdermal drug delivery (TDD). TDD has long held the promise of non-invasive drug delivery, adding convenience, reduced costs, and improved patient compliance via the application of a patch to the skin. The missing components in TDD have been controlled release of the drug carried in the patch and the breadth of drugs that can actually be transferred through the skin. Iontera’s patented IonIQ technology intelligently enhances and controls delivery via a single-electrode design that is governed by a programmable onboard computer.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $3.7M
- Last round: Series Unknown (Oct 2014)
- Website: iontera.com
- Phone: 14014150440
Industries & Categories
Hardware, Health Care, Medical
Canonical: https://fsome.com/organization/iontera-2867535 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.